Mad Money 03/19/26 | Audio Only
Speakers
Jim Cramer -- Host, Mad Money
— CNBC host, Mad Money
Summary
- Market Sentiment & Strategy: Cramer argues the market is extremely oversold based on multiple indicators: AAII sentiment shows 52% bearishness (vs. 30.4% bulls), CNN's Fear & Greed Index is in "Extreme Fear," and the Market Edge oscillator hit -7.5. Historical precedent suggests a high probability of a meaningful rally within 30 days from such levels.
- Macro Context: The recent sell-off is attributed to geopolitical risk (attacks on oil/gas fields in the Middle East) spiking energy prices and fears of a global recession, which overshadowed positive company-specific news.
- Five Below (FIVE) Turnaround: The company reported a blowout quarter (15.4% comps vs. 14.5% expected, EPS of $4.31 vs. $4.00) and issued strong guidance. Cramer credits new CEO Winnie Park for a successful strategy shift focusing on target demographics (Gen Alpha/Z, Millennial moms), social media integration, and streamlined operations.
- Johnson & Johnson (JNJ) Opportunity: The FDA approved JNJ's oral psoriasis drug, icotidib. Cramer sees this as a major positive overlooked by the market, as it directly challenges AbbVie's injectable Skyrizi in a multi-billion dollar market. He believes the stock's pullback is a buying opportunity.
- Signet Jewelers (SIG) Execution: The company reported robust results and strong cash flow ($525M, up 20% YoY). CEO JK Seamanic highlighted a simplified operating model (focusing on core brands Kay and Jared), balanced growth across lab-grown and natural diamonds, and planned investments in digital and store experience.
- Stock Selection Philosophy: Cramer advocates buying high-quality companies in "free fall" if the underlying business thesis is intact, using Dell Technologies as a past example where buying on the way down during an AI-related sell-off paid off.
- Lightning Round Takeaways: Cramer expressed negative views on Stellantis (STLA) and Skyworks Solutions (SWKS), citing fundamental issues, while showing interest in learning more about Element Solutions.
Trade Ideas
Cramer stated, "I'm sticking by Reddit... I'd like to buy some stock right here at 27 times earnings." He called it an "incredibly valuable property" that charges too little for advertising and has a very active user base. The stock has declined (~30% from the caller's cost basis), but Cramer believes the fundamental value and platform engagement are strong, making the current price attractive. The oversold market condition and the stock's specific decline present a buying opportunity for a company he views as fundamentally sound and undervalued. Failure to monetize its user base effectively; continued negative market sentiment dragging on price.
Cramer detailed Five Below's "spectacular quarter" where it beat comps and EPS estimates and issued guidance far above Street expectations (e.g., Q1 EPS guide of $1.50-$1.69 vs. $0.97 estimate). The turnaround under CEO Winnie Park, involving a focus on target customers, social media integration, and better in-store execution, is driving superior growth versus dollar store peers. Strong execution and management's new strategy are sustainable competitive advantages, suggesting the stock has more room to run despite already tripling in the last 12 months. Consumer spending weakness at the lower end; failure to maintain operational agility and trend relevance.
When asked about Skyworks, Cramer said, "Problem with Skyworks is that it's totally cell phone. It just doesn't have enough. It's got to merge with someone." The company is viewed as overly reliant on the cyclical smartphone market with insufficient diversification, limiting its growth potential and investment appeal. Lack of a compelling, diversified business model makes the stock unattractive in the current tech landscape. A successful merger or diversification into new, high-growth markets.
In the Lightning Round, when asked about Stellantis, Cramer said, "I just can't recommend it... Don't buy. Don't buy. Don't buy." He noted it was hitting another 52-week low. The stock is in a persistent downtrend ("house of pain") with no positive catalyst mentioned. The fundamental outlook is poor, and the price action is consistently negative, making it an unattractive investment. A sudden turnaround in the company's operations or market segment.
Cramer stated the FDA approval for JNJ's oral psoriasis pill, icotidib, is "terrific news" that was ignored due to a bad market day. He believes it could "eat [AbbVie's Skyrizi] alive" in a large market and calls the stock's pullback a "great buying opportunity." The oral formulation is preferred over injectables, giving JNJ a potential edge. The drug also has a pipeline for other indications, with peak sales estimates ranging from $5B to $7.5B. The positive development is company-specific and significant, but the stock price did not react due to macro noise (oil prices), creating a mispricing. Pricing and market uptake challenges against entrenched competitors; broader market decline persists.
Following the interview with CEO JK Seamanic, Cramer concluded, "This stock is one of the things we're going to be thinking about as a great retailer." He praised the simplified operating model, strong cash flow generation, and balanced growth across income bands and diamond types. The company's focus on core brands (Kay, Jared), healthy balance sheet, and planned investments in digital and store experience position it for sustained organic growth. The market is not giving the company full credit for its operational improvements and financial strength, making it attractive. Deterioration in consumer discretionary spending; execution missteps in digital transformation.
